Biological Comparison of a Novel Insulin DPI Formulation to Exubera

Inhaled peptides and proteins show great promise for respiratory and systemic disease treatment. This class of molecules is particularly well suited to formulation and processing by spray-drying to achieve respirable engineered particles. This webinar describes formulation and process development for a novel inhaled biotherapeutic, an insulin dry-powder inhalation (DPI) formulation, as well as important preclinical in vivo modeling methodologies required to understand biologic performance. The performance of the novel spray-dried powder is compared to that of Exubera™.